黛力新联合伊托必利治疗难治性胃食管反流病的临床研究

A clinical study of deanxit combined with itopride in the treatment of refractory gastroesophageal reflux disease

目的探讨黛力新联合伊托必利治疗难治性胃食管反流病的临床效果,为临床疗提供理论依据。方法选取2019年1月~2020年1月于我院消化内科就诊的胃食管反流病患者100例为研究对象,依据患者入院先后顺序随机分为对照组和实验组,每组50例,对照组患者实行常规方案治疗,实验组患者在常规方案治疗的基础上,加用黛力新联合伊托必利口服治疗,比较两组患者治疗前后胃食管反流症状、焦虑和抑郁等症状,并采用胃食管反流病诊断问卷进行症状积分比较。比较两组的治疗效果,比较分析两组患者在各项临床症状指标、不良反应发生率方面的差异。结果实验组患者治疗后症状好转例数显著多于对照组,差异有统计学意义(P<0.05);两组患者治疗过程中均未出现明显不良反应,实验组患者治疗总有效率为88%,显著高于对照组的66%,差异有统计学意义(P<0.05);实验组治疗后焦虑、抑郁状态改善程度显著优于对照组,差异有统计学意义(P<0.05)。结论黛力新联合伊托必利治疗难治性胃食管反流病可取得更好疗效,显著改善患者焦虑、抑郁状态,值得临床推广使用。

Objective To explore the clinical effect of deanxit combined with itopride in the treatment of refractory gastroesophageal reflux disease(RGRD),and to provide a theoretical basis for the treatment of clinical diseases.Methods A total of 100 patients with gastroesophageal reflux disease who were treated in the Department of Gastroenterology of our hospital from January 2019 to January 2020 were selected as the subjects of research.According to the admission order of the patients,they were randomly divided into the control group and the experimental group,with 50 patients in each group.The patients in the control group were treated with the conventional regimen,while the patients in the experimental group were additionally treated with deanxit combined with itopride orally in addition to the conventional regimen.The symptoms of gastroesophageal reflux symptoms,anxiety and depression,etc.of the two groups of patients before and after treatment were compared,and symptom scores were calculated with the diagnostic questionnaire of gastroesophageal reflux disease.The therapeutic efficacy was compared between the two groups,and the differences between the two groups of patients in various clinical symptom indexes and the incidence rate of ADRs were analyzed through comparisons.Results The number of patients in the experimental group with ameliorated symptoms after treatment was significantly larger than that in the control group,with statistically significant difference(P<0.05).No obvious ARDs occurred in the treatment process of both the two groups of patients.The total effective rate of treatment in the patients of the experimental group was 88%,significantly higher than the 66%of the control group,and the difference was statistically significant(P<0.05).After treatment,the amelioration degree of anxiety and depression in the experimental group were significantly superior than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Deanxit combined with itopride can achieve better efficacy in the treatment of RGRD,and it can significantly relieve the patient's anxiety and depression.It is worthy of clinical promotion and application.